Immatics announced that a pediatric patient with advanced metastatic nephroblastoma achieved deep and durable remission after treatment with a PRAME-directed TCR T-cell therapy using Immatics' TCR, with response ongoing at six months of follow-up.
Key takeaways
A 17-year-old pediatric patient with PRAME-positive advanced nephroblastoma achieved deep remission after treatment with Immatics' PRAME-directed TCR T-cell therapy, with response ongoing at six months.
The patient had rapidly progressing disease with metastases to lung, liver and brain and had exhausted all available treatment options before receiving the experimental treatment.
Safety events included manageable cytokine release syndrome that resolved under treatment, and the patient is in excellent physical condition at six months follow-up.
Immatics is planning to evaluate its PRAME TCR T-cell therapy candidates in pediatric patients, including a potential first-in-pediatrics Phase 1/2 basket study at KiTZ in Heidelberg.
PRAME is expressed in more than 50 cancers and Immatics has the broadest PRAME franchise with three product candidates across cell therapies and bispecifics.
The data will be presented in a late-breaking poster at the AACR Annual Meeting 2026 on April 21, 2026, by Dr. Christian M. Seitz from KiTZ.